Fluifort Mechanism of Action

Pharmacology: Therapeutic Properties: FLUIFORT (Carbocysteine Lysine Salt Monohydrate) is a muco-regulator which exerts a specific metabolic action on the serous and mucous cells of the respiratory epithelium. It has no effect on the mucus itself.
The main demonstrated effect of FLUIFORT is the increase of sialomucin contents in the mucus, restoring the proper sialo- to fucomucin proportion. This directly results in restored physiological mucus viscosity, elasticity and adhesion, and indirectly in restoring mucus hydration and mucociliary clearance.
The salification of Carbocysteine with Lysine results in greater solubility and biological availability, which allows to decrease the number of daily administrations while maintaining the wanted effects, and with an increase of the post-dosing effect typical of metabolic agents.
Once the metabolic mechanism is activated - that is, after one or a few days of administration, depending on the specific condition of the patient - it remains in effect even in the absence of drug administration (post-dosing carry-over effect).
Pharmacokinetics: Carbocysteine Lysine Salt Monohydrate has a greater water solubility and hence improved bio-availability. Therefore it is possible to administer FLUIFORT once daily in adults and twice daily in children.
The active ingredient is rapidly and completely absorbed after oral administration (plasma half-life 1.5 hour). It is mainly excreted via the urinary route; 30-60% is excreted unmodified; the remainder in the form of various metabolites. Bio-availability studies have shown that up to 17.5% of the administered dose can be found in the bronchial secretions.